SIGA Technologies

A long awaited trial verdict for SIGA Technologies (NASDAQ: SIGA) is poised to be revealed in the coming weeks, as investors are eager to see whether the company will hold on to exclusive rights for its lead drug, ST-246. ST-246 is the world's first treatment for smallpox, a potential bioterrism...

Wedbush Securities has raised the price target on SIGA Technologies (NASDAQ: SIGA) from $17 to $23 and maintains its Outperform rating.

James Altucher has taken an interesting look at Pharmathene, Inc. (AMEX: PIP), a company he believes can go from its current price, $2.64, to $20 or higher. There are two reasons for his prediction. The first relates to a lawsuit against SIGA Technologies, Inc. (NASDAQ: SIGA), a company that was...